Cell TherapyCell therapy holds out great promise for the treatment of a variety of diseases and conditions. Primary cells can be engineered to express a wide range of therapeutic proteins. One rate limiting step in the field is the relatively low frequency of successful cell engineering. Chromovert technology represents an enabling technology to enrich engineered primary cells for subsequent implantation. Chromocell is currently working with three leading academic institutions in the area of primary cell engineering and enrichment.
One project focuses on enriching engineered primary cells for treatment of neovascular pathologies. The second involves isolation of a successfully manipulated stem cell population for treatment of immunodeficiency. The aim of the final project is to enable the creation of embryonic stem cells from individual patients.
about chromovert
